|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2011-6-2
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Stimulating an immune response against cancer with the use of vaccines remains a challenge. We hypothesized that combining a melanoma vaccine with interleukin-2, an immune activating agent, could improve outcomes. In a previous phase 2 study, patients with metastatic melanoma receiving high-dose interleukin-2 plus the gp100:209-217(210M) peptide vaccine had a higher rate of response than the rate that is expected among patients who are treated with interleukin-2 alone.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1533-4406
|
|
pubmed:author |
pubmed-author:BalkissoonJaiJ,
pubmed-author:ChoykePeterP,
pubmed-author:ConlonKevinK,
pubmed-author:ConryRobert MRM,
pubmed-author:CurtiBrendanB,
pubmed-author:GailaniFawazF,
pubmed-author:GonzalezReneR,
pubmed-author:HwuPatrickP,
pubmed-author:KaufmanHowardH,
pubmed-author:KendraKari LKL,
pubmed-author:KuzelTimothy MTM,
pubmed-author:LawsonDavid HDH,
pubmed-author:LemingPhillip DPD,
pubmed-author:MarincolaFrancesco MFM,
pubmed-author:MerinoMaria JMJ,
pubmed-author:MillerDonald MDM,
pubmed-author:PockajBarbaraB,
pubmed-author:ReintgenDouglas SDS,
pubmed-author:RichardsJon MJM,
pubmed-author:RileyLeeL,
pubmed-author:RosenbergSteven ASA,
pubmed-author:SchwartzentruberDouglas JDJ,
pubmed-author:TreismanJonathanJ,
pubmed-author:VenaDonD,
pubmed-author:WhiteRichard LRL,
pubmed-author:WhitmanEric DED
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
2
|
|
pubmed:volume |
364
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2119-27
|
|
pubmed:dateRevised |
2011-8-26
|
|
pubmed:meshHeading |
pubmed-meshheading:21631324-Adult,
pubmed-meshheading:21631324-Antineoplastic Agents,
pubmed-meshheading:21631324-Cancer Vaccines,
pubmed-meshheading:21631324-Disease-Free Survival,
pubmed-meshheading:21631324-Female,
pubmed-meshheading:21631324-Humans,
pubmed-meshheading:21631324-Interleukin-2,
pubmed-meshheading:21631324-Male,
pubmed-meshheading:21631324-Melanoma,
pubmed-meshheading:21631324-Middle Aged,
pubmed-meshheading:21631324-Skin Neoplasms,
pubmed-meshheading:21631324-Survival Analysis
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
|
|
pubmed:affiliation |
Indiana University Health Goshen Center for Cancer Care, Goshen, IN 46526, USA. dschwart@iuhealth.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III,
Research Support, N.I.H., Extramural
|
